May 12, 2020 / 12:20PM GMT
Geoffrey Christopher Meacham - BofA Merrill Lynch, Research Division - Research Analyst
Okay, everyone, good morning. Welcome to the virtual Vegas conference at Bank of America. This is our first session this morning. We're really happy to have Regeneron this morning presenting. Speaking on behalf of Regeneron is Marion McCourt, who is Senior Vice President and Head of Commercial. Marion, you there?
Marion E. McCourt - Regeneron Pharmaceuticals, Inc. - SVP of Commercial
I am, Geoff, and hello to everybody. Pleasure to join you today.
Questions and Answers:
Geoffrey Christopher Meacham - BofA Merrill Lynch, Research Division - Research AnalystOkay. Great. So we'll do a Q&A here with the team, and there is an ability to ask a question online as well, if listeners want to do that.
So Marion, let's talk post the first quarter. So it looked like EYLEA sales held up probably a bit better than people thought in the first quarter. Looking to 2Q, what's your expectation for the persistency rates in the
Trustpilot
